Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NasdaqGS:PLCE
NasdaqGS:PLCESpecialty Retail

Children’s Place (PLCE) Q3 Loss Reinforces Bearish Narrative on Profitability and Turnaround Prospects

Children's Place (PLCE) just turned in a mixed Q3 2026 update, with revenue of about $339 million and a basic EPS loss of roughly $0.19 as the retailer continues to work through a difficult turnaround. The company has seen quarterly revenue move from around $320 million in Q2 2025 to $390 million in Q3 2025 and then to $339 million this quarter, while EPS has swung from a $2.51 loss in Q2 2025 to a $1.57 profit in Q3 2025 and back to losses of $0.24 in Q2 2026 and $0.19 in Q3 2026. This...
NYSE:HI
NYSE:HIMachinery

Hillenbrand (HI): Is the Recent 25% 90-Day Climb Justified by Its Valuation?

Hillenbrand (HI) has quietly ground higher this past quarter, leaving some investors wondering what is driving the move and whether the current price still reflects a reasonable entry point. See our latest analysis for Hillenbrand. At around $31.70, the recent 90 day share price return of roughly 25 percent suggests sentiment has turned more constructive, even though the longer term total shareholder returns have been negative. If Hillenbrand has you rethinking where the next leg of...
ENXTAM:LKFT
ENXTAM:LKFTBiotechs

Did Strong GLPG5101 CAR T Data and Decentralized Manufacturing Just Shift Galapagos' (ENXTAM:GLPG) Investment Narrative?

Earlier in December 2025, Galapagos NV reported updated Phase 2 results from its ATALANTA-1 trial of CD19 CAR T-cell therapy GLPG5101 in heavily pretreated mantle cell lymphoma, showing very high response rates, durable outcomes at nine months, and an encouraging safety profile presented at the ASH Annual Meeting. Beyond efficacy, the trial also highlighted the feasibility of decentralized manufacturing, with most patients receiving a fresh GLPG5101 product within seven days of apheresis,...